Core Viewpoint - Chutian Technology Co., Ltd. reported a revenue decline of 6.60% year-on-year for the first three quarters of the year, but achieved a significant net profit increase of 145.11% due to strategic adjustments and cost reduction measures [1] Group 1: Financial Performance - For the first three quarters, the company achieved a revenue of 3.896 billion yuan, down 6.60% year-on-year, while the net profit attributable to shareholders was 84.4635 million yuan, up 145.11% [1] - In the third quarter, the company reported a revenue of 1.479 billion yuan, an increase of 10.17% year-on-year, and a net profit of 96.7681 million yuan, up 192.50% [1] - The company's operating costs for the first three quarters were 2.682 billion yuan, a decrease of 13.19% year-on-year, with selling and administrative expenses also declining [3] Group 2: Strategic Adjustments - Chutian Technology has actively adjusted its business strategy since the second half of last year, focusing on international market expansion and reducing low-margin projects domestically [1] - The company has segmented its global market into five regions and tailored its sales services to enhance international competitiveness, achieving breakthroughs in Europe, the Middle East, and Southeast Asia [2] - The company plans to implement a series of operational reforms starting in the second half of 2024, including optimizing product solutions, streamlining procurement costs, and improving production efficiency [3] Group 3: Market Expansion and Innovation - The company hosted the 2025 Vietnam Biopharmaceutical Summit, enhancing its regional visibility and laying a solid foundation for future market expansion [2] - Chutian Technology participated in the World Pharmaceutical Raw Materials and Machinery Exhibition in Frankfurt, showcasing innovative core equipment to the global market [3] - The company is advancing its layout in niche markets such as medical aesthetics and peptides, aiming to open new avenues for revenue growth [3]